These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 33675325)

  • 1. NAT2 polymorphisms as a cause of metamizole-induced agranulocytosis.
    Radulovic I; Dogan B; Dohna-Schwake C; Schündeln MM; Siffert W; Möhlendick B
    Pharmacogenet Genomics; 2021 Aug; 31(6):140-143. PubMed ID: 33675325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-immunological toxicological mechanisms of metamizole-associated neutropenia in HL60 cells.
    Rudin D; Lanzilotto A; Bachmann F; Housecroft CE; Constable EC; Drewe J; Haschke M; Krähenbühl S
    Biochem Pharmacol; 2019 May; 163():345-356. PubMed ID: 30653950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender and functional CYP2C and NAT2 polymorphisms determine the metabolic profile of metamizole.
    Martínez C; Andreu I; Amo G; Miranda MA; Esguevillas G; Torres MJ; Blanca-López N; Blanca M; García-Martín E; Agúndez JA
    Biochem Pharmacol; 2014 Dec; 92(3):457-66. PubMed ID: 25241292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case Report: Simultaneously Induced Neutropenia and Hemolysis After a Single Metamizole Dose.
    Allgaier R; Kandulski A; Gülow K; Maier L; Müller M; Tews HC
    Drugs R D; 2023 Jun; 23(2):93-98. PubMed ID: 36988798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicity of metamizole on differentiating HL60 cells and human neutrophil granulocytes.
    Rudin D; Roos NJ; Duthaler U; Krähenbühl S
    Toxicology; 2019 Oct; 426():152254. PubMed ID: 31356851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metamizole and the risk of drug-induced agranulocytosis and neutropenia in statutory health insurance data.
    Klose S; Pflock R; König IR; Linder R; Schwaninger M
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Apr; 393(4):681-690. PubMed ID: 31811328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Agranulocytosis induced by metamizole and its management with granulocyte growth factor].
    Celeketić D; Trpković A; Cvetković Z
    Vojnosanit Pregl; 2005 Jan; 62(1):79-82. PubMed ID: 15715354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A possible increased risk of metamizole-associated neutropenia among COVID-19 patients.
    Lerman TT; Sagi M; Shafir Y; Sheena L; Cohen E; Goldberg E; Krause I
    Br J Clin Pharmacol; 2021 Jul; 87(7):2902-2906. PubMed ID: 33332642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paediatric Agranulocytosis Associated with Metamizole Treatment.
    Kılıç Ö; İşeri Nepesov M; Ulukapı HB; Özdemir ZC; Bör Ö; Dinleyici EÇ
    Paediatr Drugs; 2021 Jan; 23(1):105-110. PubMed ID: 33247375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical otorhinolaryngological symptoms of metamizole-induced agranulocytosis].
    Send T; Westermann S; Eichhorn KW; Jakob M
    HNO; 2015 Mar; 63(3):215-9. PubMed ID: 25515122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of agranulocytosis with metamizole in comparison with alternative medications based on health records in Spain.
    Maciá-Martínez MÁ; Castillo-Cano B; García-Poza P; Martín-Merino E
    Eur J Clin Pharmacol; 2024 Oct; 80(10):1503-1514. PubMed ID: 38907883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metamizole (Dipyrone) and the Liver: A Review of the Literature.
    Lutz M
    J Clin Pharmacol; 2019 Nov; 59(11):1433-1442. PubMed ID: 31433499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Metamizole (dipyrone): mode of action, drug-drug interactions, and risk of agranulocytosis].
    Lampl C; Likar R
    Schmerz; 2014 Dec; 28(6):584-90. PubMed ID: 25199942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Leukopenia with unclear fever].
    Mayer S; Kündiger T; Schrader H
    Internist (Berl); 2017 Jul; 58(7):740-744. PubMed ID: 28265684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unmasking of Metamizole-induced Liver Injury by Simult aneous Development of Characteristic Agranulocytosis.
    Lutz M; Grünewald I; Lenze F; Heinzow H; Ullerich H; Kabar I; Schmidt HH; Tepasse PR
    Curr Drug Saf; 2023; 18(3):404-412. PubMed ID: 35670337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Agranulocytosis after use of metamizole - an underestimated risk?].
    Schinz K; Waldfahrer F; Wüst W; Iro H
    Laryngorhinootologie; 2020 Oct; 99(10):707-712. PubMed ID: 32588405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agranulocytosis attributed to metamizole: An analysis of spontaneous reports in EudraVigilance 1985-2017.
    Hoffmann F; Bantel C; Jobski K
    Basic Clin Pharmacol Toxicol; 2020 Feb; 126(2):116-125. PubMed ID: 31449718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Life-threatening agranulocytosis, anemia, and plasmacytosis after dipyrone use for fever in a child.
    Işık M; Kaya Z; Belen FB; Aktaş AT; Tezer H; Gürsel T
    J Pediatr Hematol Oncol; 2014 Jan; 36(1):e46-8. PubMed ID: 23007418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective study of the incidence of agranulocytosis and aplastic anemia associated with the oral use of metamizole sodium in Poland.
    Maj S; Centkowski P
    Med Sci Monit; 2004 Sep; 10(9):PI93-5. PubMed ID: 15328493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutropenia, agranulocytosis and dipyrone.
    Hamerschlak N; Cavalcanti AB
    Sao Paulo Med J; 2005 Sep; 123(5):247-9. PubMed ID: 16358101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.